Presentation Description:
HCT is frequently offered as a curative option for children with benign and malignant conditions. Improvements in HCT strategies have increased survival by approximately 10% per decade. In fact, long-term survival is an expected outcome for many children and adolescents who undergo HCT. The growing population of long-term survivors has brought to the medical forefront a host of chronic and debilitating conditions attributed to toxicity from pre-transplantation exposure, transplantation conditioning regimens, chronic immunosuppression, and GVHD. This presentation provided an overview of health-related outcomes in long-term survivors of childhood HCT, and compared these outcomes to survivors of conventionally treated cancer.

Speaker:

Saro Armenian, DO, MPH
Medical Director, Pediatric Survivorship Clinic, Childhood Cancer Survivorship Program
City of Hope, Los Angeles